GSK and Merck could supply discounted cervical cancer vaccines to developing countries

As reported by Reuters, The Global Alliance for Vaccines and Immunisation are near to closing a deal whereby discounted cervical cancer vaccines made by Merck and GlaxoSmithKline (GSK) could be supplied to women in developing countries.

The vaccines are Merck’s Gardasil and GSK’s Cervarix which protect against the main cause of cervical cancer – human papillomavirus (HPV). Experts believe that 85 per cent of the 275,000 cervical cancer deaths per year happen in developing nations. These vaccines could have a really positive impact on the survival rates of cervical cancer patients in these countries.

A spokesperson from GAVI said they were close to coming to a deal whereby the pharmaceutical companies could offer the cervical cancer vaccinations at a reduced rate. However, the organisation will not give any further information regarding price and said to be still working with pharmaceutical companies to come to an acceptable price.

Are you looking for a new pharmaceutical job in the UK or EU? Click here to search our current pharmaceutical jobs online now.

Posted in: Industry News, News
CK Logo in place of featured image